Skip to main content
. Author manuscript; available in PMC: 2018 Mar 28.
Published in final edited form as: Cancer Lett. 2016 Dec 30;389:41–48. doi: 10.1016/j.canlet.2016.12.030

Fig. 8.

Fig. 8

Effects of SRI36160 and niclosamide on STAT3 and mTORC1 signaling in PANC-1 and DLD-1 cells. Cancer cells in 6-well plates were treated with SRI36160 or niclosamide at the indicated concentrations for 24 h. The levels of STAT3, phopho-STAT3, S6 and phospho-S6 were examined by Western blotting. All the samples were also probed with anti-actin antibody to verify equal loading.